标题：趋化因子配体18在乳腺癌组织中的表达及意义

      作者：张晓申 1，高 进 1，郑文博 1，叶熹罡 1，唐 炜 1，陈 伦 1，潘凌霄 1，李 君 2
    (广州医学院第一附属医院乳腺外科 1、肝胆外科 2，广东 广州 510120)

      卷次： 2013年24卷19期

      【摘要】 目的 探讨趋化因子配体18 (CCL18)在乳腺癌组织中的表达及意义。方法 选取我院乳腺外科
2009年12月至2012年6月经病理确诊为乳腺癌患者组织标本80例，良性乳腺病患者组织标本40例，另取良性乳腺
病患者病灶周边的正常乳腺组织20例作为对照组，全部入组病例为女性。采用免疫组化Envision方法，对标本检测
CCL18的表达，并分析CCL18及Ki67在乳腺癌组的表达情况。结果 CCL18在对照组、良性乳腺病组均无表达，
在乳腺癌组阳性率为71.25% (57/80)；CCL18在乳腺癌组的表达与肿瘤的大小、病理分期、淋巴结转移个数呈正相
关。CCL18在乳腺癌组织的表达与Ki67无相关性(P=0.091)。结论 CCL18可作为乳腺癌的生物学指标，与乳腺癌
的浸润性及转移有一定的关系，但与肿瘤细胞的增殖无关，对认识乳腺癌的生物学特性以及判断预后有重要意义。

      【关键词】 乳腺癌；趋化因子配体18(CCL18)；Ki67

      【中图分类号】 R737.9 【文献标识码】 A 【文章编号】 1003—6350（2013）19—2815—03


Expression and significance of CCL18 in breast cancer.
ZHANG Xiao-shen 1, GAO Jin 1, ZHENG Wen-bo 1, YE
Xi-gang 1, TANG Wei 1, CHEN Lun 1, PAN Ling-xiao 1, Li Jun 2. Department of Breast Surgery 1, Department of
Hepatobiliary Surgery 2, the First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, Guangdong, CHINA

【Abstract】 Objective To investigate the expression and significance of Chemokine CC-motif ligand 18
(CCL18) in breast cancer. Methods Eighty tissue samples from patients with breast cancer (breast cancer group), 40
tissue samples from patients with benign breast diseases (benign breast diseases), and 20 healthy tissue samples aside
the benign lesions from the patients with benign breast disease (the control group) were collected in the Department of
Breast Surgery of our hospital from December 2009 to June 2012. Envision immunohistochemical method was used to
examine the expression of CCL18, and SP immunohistochemical method was applied to examine the expression of
Ki67. The correlation between the expression of CCL18 and Ki67 in breast cancer was analyzed. All the patients col-
lected were female. Results There was no CCL18 expressed in the control group and the benign breast diseases
group, but 57 cases in the breast cancer group showed positive results, with the positive rate of 71.25%. Obviously, the
expression level of CCL18 in the breast cancer group was significantly higher than the other two groups (P<0.001),
and it increased with higher tumor burden defined by tumor size (P=0.035), staging (P<0.001), and lymphovascular in-
vasion (P<0.001). No significant correlation was found between the expression level of CCL18 and Ki67 (P=0.091).
Conclusion CCL18 is the marker of breast cancer. High expression of CCL18 in breast cancer has a relationship
with tumor invasion and metastasis, but is unrelated to the proliferation of cancer cells. CCL18 is of great importance
for studying the bionomics of breast cancer and evaluating the prognosis of breast cancer.

      【Key words】 Breast cancer; Chemokine CC-motif ligand 18 (CCL18); Ki67